Connection

Ki Chung to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Ki Chung has written about Antibodies, Monoclonal.
Ki Chung
Connection Strength
0.371
Antibodies, Monoclonal
  1. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28(21):3485-90.
    View in: PubMed
    Score: 0.278
  2. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007 Jul 01; 25(19):2691-5.
    View in: PubMed
    Score: 0.057
  3. A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. Oncologist. 2021 09; 26(9):e1499-e1507.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.